Investigating urinary tract infections caused by resistant bacteria in women
Official title: Community-onset urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in women of diverse backgrounds
Funded at University of California, San Francisco · NIH-10992196 · Data updated 2026-11-12
This study is looking at urinary tract infections (UTIs) caused by a specific type of bacteria in women from different backgrounds to find out what factors might increase the risk of these infections and how to prevent them better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | December 1, 2021 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $201,150 |
| NIH project number | 5K23AI166030-04 |
| Project ID | NIH-10992196 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women experiencing community-onset urinary tract infections, particularly those from diverse backgrounds.
✕Less likely to help
Patients who do not have urinary tract infections or those who are not women may not receive any benefit from this research.
What this research studies
This research focuses on understanding community-onset urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase-producing Escherichia coli in women from diverse backgrounds. The study aims to identify demographic and neighborhood-level risk factors associated with these infections, as well as complications and trends in prevalence. By combining epidemiological methods, the research seeks to uncover novel risk factors that could be targeted for prevention and improved outcomes. The project is led by Dr. Eva Raphael, who is receiving training to enhance her skills as a clinician-researcher in this field.
Why it matters
Potential benefit: If successful, this research could lead to better prevention strategies and treatment options for women suffering from antibiotic-resistant urinary tract infections.
How similar studies have gone: Previous research has shown success in identifying risk factors for infections caused by antibiotic-resistant bacteria, indicating that this approach has potential for meaningful findings.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Raphael, Eva — University of California, San Francisco
- Study coordinator: Raphael, Eva
Related research
Other NIH-funded projects on the same topics.
-
New ways to stop urinary tract infections by blocking bacterial adhesion
A study to test new methods that prevent bacteria from sticking to urinary tract tissues and devices, potentially stopping infections before they start.
-
Hybridization capture sequencing to quickly identify canine urinary pathogens and resistance genes
A new sequencing approach directly from dog urine aims to rapidly identify bacteria causing urinary infections and their drug-resistance profiles to guide treatment.
-
Enterococcal Proteases and CAUTI: How the body’s environment activates bacteria to cause infections
A small grant is exploring how two enzymes from Enterococcus faecalis interact with the urine environment to drive catheter-associated urinary tract infections and why these infections are hard to treat.
-
Daily nitrofurantoin with or without bladder cauterization to prevent recurrent bladder infections in women
This study tests two approaches to prevent recurrent bladder infections in women: taking a low-dose antibiotic every day versus adding a bladder cauterization procedure plus the same daily antibiotic.
-
New bacterial pathway that helps cause bladder infections
Researchers are exploring how bacteria steal nutrients in the bladder and how the body fights them to help people with urinary tract infections.
-
New oral antifungal for tough Candida UTIs
A Johns Hopkins team is testing a new oral antifungal medicine called fungerps to treat urinary tract infections caused by azole-resistant Candida fungi.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.